BBOT
BridgeBio Oncology Therapeutics, Inc.
NASDAQ: BBOT · HEALTHCARE · BIOTECHNOLOGY
$8.41
+4.34% today
Updated 2026-04-30
Market cap
$702.69M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-4.30
Dividend yield
—
52W range
$8 – $15
Volume
0.3M
BridgeBio Oncology Therapeutics, Inc. (BBOT) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | — | — | $0.00 | $0.00 | $0.00 |
| Revenue growth (YoY) | — | — | — | — | — |
| Cost of revenue | — | — | — | — | $610000.00 |
| Gross profit | — | — | — | — | $-610000.00 |
| Gross margin | — | — | — | — | — |
| R&D | — | — | $56.29M | $73.11M | $121.20M |
| SG&A | $74326.00 | $3520.00 | $8.48M | $7.76M | $24.62M |
| Operating income | $-43357.00 | $-3520.00 | $-64.77M | $-80.86M | $-145.82M |
| Operating margin | — | — | — | — | — |
| EBITDA | $-43357.00 | $-3520.00 | $-64.68M | $-80.66M | $-145.82M |
| EBITDA margin | — | — | — | — | — |
| EBIT | — | — | $-64.77M | $-80.86M | — |
| Interest expense | — | — | — | — | — |
| Income tax | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-43357.00 | $-3520.00 | $-64.70M | $-74.28M | $-134.04M |
| Net income growth (YoY) | — | +91.9% | -1837939.8% | -14.8% | -80.5% |
| Profit margin | — | — | — | — | — |